World Journal of Surgery

, Volume 34, Issue 10, pp 2393–2398 | Cite as

Is Hypoalbuminemia an Independent Prognostic Factor in Patients with Gastric Cancer?

  • Andrew B. C. Crumley
  • Robert C. Stuart
  • Margaret McKernan
  • Donald C. McMillan
Article

Abstract

Background

Studies have indicated that hypoalbuminemia is associated with decreased survival of patients with gastric cancer. However, the prognostic value of albumin may be secondary to an ongoing systemic inflammatory response. The aim of the study was to assess the relation between hypoalbuminemia, the systemic inflammatory response, and survival in patients with gastric cancer.

Methods

Patients diagnosed with gastric carcinoma attending the upper gastrointestinal surgical unit in the Royal Infirmary, Glasgow between April 1997 and December 2005 and who had a pretreatment measurement of albumin and C-reactive protein (CRP) were studied.

Results

Most of the patients had stage III/IV disease and received palliative treatment. The minimum follow-up was 15 months. During follow-up, 157 (72%) patients died of their cancer. On univariate analysis, stage (p < 0.001), treatment (p < 0.001), albumin level (p < 0.001), and CRP level (p < 0.001) were significant predictors of survival. On multivariate analysis, stage (p < 0.001), treatment (p < 0.001), and CRP level (p < 0.001) remained significant predictors of survival. Albumin was no longer an independent predictor of survival.

Conclusions

Low albumin concentrations are associated with poorer survival in patients with gastric cancer. However, the strength of this relation with survival is dependent on the presence of a systemic inflammatory response, as evidenced by an elevated CRP level. Therefore, it appears that the relation between hypoalbuminemia and poor survival is secondary to that of the systemic inflammatory response.

References

  1. 1.
    Cancer Research UK Information Resource Centre (2004) CancerStats. http://info.cancerresearchuk.org/cancerstats
  2. 2.
    Allgayer H, Heiss MM, Schildberg FW (1997) Prognostic factors in gastric cancer. Br J Surg 84:1651–1664CrossRefPubMedGoogle Scholar
  3. 3.
    Pyrhonen S, Kuitunen T, Nyandoto P et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591PubMedGoogle Scholar
  4. 4.
    Ross P, Nicolson M, Cunningham D et al (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996–2004CrossRefPubMedGoogle Scholar
  5. 5.
    Lien YC, Hsieh CC, Wu YC et al (2004) Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardia. J Gastrointest Surg 8:1041–1048CrossRefPubMedGoogle Scholar
  6. 6.
    Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D et al (2007) Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 14:381–389CrossRefPubMedGoogle Scholar
  7. 7.
    Alici S, Kaya S, Izmirli M et al (2006) Analysis of survival factors in patients with advanced-stage gastric adenocarcinoma. Med Sci Monit 12:CR221–CR229PubMedGoogle Scholar
  8. 8.
    Lee J, Lim T, Uhm JE et al (2007) Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 18:886–891CrossRefPubMedGoogle Scholar
  9. 9.
    Onate-Ocana LF, Becker M, Carrillo JF et al (2008) Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. J Surg Oncol 98:336–342CrossRefPubMedGoogle Scholar
  10. 10.
    McMillan DC, Crozier JE, Canna K et al (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22:881–886CrossRefPubMedGoogle Scholar
  11. 11.
    Al Murri AM, Bartlett JM, Canney PA et al (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94:227–230CrossRefPubMedGoogle Scholar
  12. 12.
    Forrest LM, McMillan DC, McArdle CS et al (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89:1028–1030CrossRefPubMedGoogle Scholar
  13. 13.
    Glen P, Jamieson NB, McMillan DC et al (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 6:450–453CrossRefPubMedGoogle Scholar
  14. 14.
    McMillan DC, Watson WS, O’Gorman P et al (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39:210–213CrossRefPubMedGoogle Scholar
  15. 15.
    Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457–1459CrossRefPubMedGoogle Scholar
  16. 16.
    Maltoni M, Caraceni A, Brunelli C et al (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations: a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23:6240–6248CrossRefPubMedGoogle Scholar
  17. 17.
    Ellegard LH, Bosaeus IG (2008) Biochemical indices to evaluate nutritional support for malignant disease. Clin Chim Acta 390:23–27CrossRefPubMedGoogle Scholar
  18. 18.
    McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67:257–262CrossRefPubMedGoogle Scholar
  19. 19.
    Morley JE, Thomas DR, Wilson MM (2006) Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83:735–743PubMedGoogle Scholar
  20. 20.
    Fearon KC, Voss AC, Hustead DS (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83:1345–1350PubMedGoogle Scholar
  21. 21.
    Ashizawa T, Okada R, Suzuki Y et al (2005) Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8:124–131CrossRefPubMedGoogle Scholar
  22. 22.
    Liao WC, Lin JT, Wu CY et al (2008) Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res 14:428–434CrossRefPubMedGoogle Scholar
  23. 23.
    Ikeguchi M, Hatada T, Yamamoto M et al (2009) Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 12:95–100CrossRefPubMedGoogle Scholar
  24. 24.
    Kim DK, Oh SY, Kwon HC et al (2009) Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 9:155CrossRefPubMedGoogle Scholar
  25. 25.
    Xu CY, Shen JG, Shen JY et al (2009) Ulcer size as a novel indicator marker is correlated with prognosis of ulcerative gastric cancer. Dig Surg 26:312–316CrossRefPubMedGoogle Scholar
  26. 26.
    Deans DA, Wigmore SJ, de Beaux AC et al (2007) Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer. Br J Surg 94:1501–1508CrossRefPubMedGoogle Scholar
  27. 27.
    Crumley AB, Stuart RC, McKernan M et al (2010) Comparison of pre-treatment clinical prognostic factors in patients with gastro-oesophageal cancer and proposal of a new staging system. J Gastrointest Surg 14:781–787CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2010

Authors and Affiliations

  • Andrew B. C. Crumley
    • 1
  • Robert C. Stuart
    • 1
  • Margaret McKernan
    • 1
  • Donald C. McMillan
    • 1
  1. 1.University Department of SurgeryRoyal InfirmaryGlasgowUK

Personalised recommendations